Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: Etiological factors or risk markers? (pages 164–173)
Annekatrin Lukanova, Susen Becker, Anika Hüsing, Helena Schock, Veronika Fedirko, Elisabeth Trepo, Antonia Trichopoulou, Christina Bamia, Pagona Lagiou, Vassiliki Benetou, Dimitrios Trichopoulos, Ute Nöthlings, Anne Tjønneland, Kim Overvad, Laure Dossus, Birgit Teucher, Heiner Boeing, Krasimira Aleksandrova, Domenico Palli, Valeria Pala, Salvatore Panico, Rosario Tumino, Fulvio Ricceri, H. Bas Bueno-de-Mesquita, Peter D. Siersema, Petra H.M. Peeters, Jose Ramon Quiros, Eric J. Duell, Esther Molina-Montes, Maria-Dolores Chirlaque, Aurelio Barricarte Gurrea, Miren Dorronsoro, Björn Lindkvist, Dorthe Johansen, Mårten Werner, Malin Sund, Kay-Tee Khaw, Nick Wareham, Timothy J. Key, Ruth C. Travis, Sabina Rinaldi, Isabelle Romieu, Marc J. Gunter, Elio Riboli, Mazda Jenab and Rudolf Kaaks
Version of Record online: 2 AUG 2013 | DOI: 10.1002/ijc.28342
Testosterone and insulin-like growth factor-1 (IGF-1) are implicated in the development of hepatocellular carcinoma (HCC), though their involvement may be more complex than previously thought. Here, in a unique study population with low prevalence of hepatitis infections, an association was detected between HCC risk and increased levels of sex hormone binding globulin (SHBG) and IGF-1 prior to diagnosis. Neither testosterone nor IGF-1, however, was found to have an etiological influence in the decade before diagnosis. The results suggest that SHBG and IGF-I should be considered in the clinical evaluation of patients at increased risk of HCC.